MAPT and Alzheimer disease: Therefore, the diagnostic criteria for vascular cognitive disorders from the International Society of Vascular Behavioral and Cognitive Disorders statement suggest excluding CSF p-tau when diagnosing vascular cognitive impairment in research (Sachdev et al., 2014), whereas a persistent increase in CSF p-tau is considered a defining biomarker of AD in the National Institute on Aging—Alzheimer’s Association Research Framework (Albert et al., 2011).